The Viral Vectors and
Plasmid DNA Manufacturing Market Outlook and
Analysis by Vector Type, by Disease Type, by Applications, by Workflow, by End
User and by Region - Forecast till 2030
Viral Vectors and Plasmid DNA Manufacturing Market Size was valued
at USD 0.3 billion in 2022 and is projected to grow from USD 0.35 Billion in
2023 to USD 0.89 billion by 2030, exhibiting a compound annual growth rate
(CAGR) of 16.90% during the forecast period (2023 - 2030).
The global viral vector and plasmid DNA manufacturing market
is driven by the rising demand for viral vector-based vaccines for infectious
diseases and a shift in the treatment paradigm of several life-threatening
diseases through advanced the rapies and technological advancements in viral
vectors.
Severalkey players are dominating the global viral vector
and plasmid DNA manufacturing market, contributing to a significant revenue
share. The prominent players are involved in organic and inorganic strategies
such asagreements, new product development & launches, mergers &
acquisitions, joint ventures, collaborations, partnershipsand geographic
expansions, to sustaintheir market positions.For instance,in April 2021,
Albumedix (UK) extended itsresearch collaboration with Cobra Biologics (US) for
the upstream and downstream processing of AAV and lentiviral vector. The
collaboration was intended for stability enhancement and process optimization
by the company.
Regional Analysis
Based on region, North America is expected to dominate the global
viral vector and plasmid DNA manufacturing market in 2020. Factors such as the
presence of a largenumber of centers and institutes engaged in the R&D of
advanced therapies and key players in this region involved in new product
launches, expansion, acquisition,and strategic collaborations are driving the
market growth. For instance, In March 2021, ABECMA (idecabtagenevicleucel), a
lentivirus-based gene therapy, received the US FDA approvalto treat R/R
multiple myeloma.
Europe is expected to hold the second-largest position in
the global viral vector and plasmid DNA manufacturing market in 2021. Key
factors attributing to the market growth are the increasing R&D spendings
to enhance research activities in the healthcare industry. For instance,
according to the data published in Eurostat in 2018, the EU spent approximately
348 USD million on Research & Development. The R&D expenditure as a
percentage of GDP was 2.18% in 2018, compared to 1.87 % in 2008.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the assessment period due to the increasing prevalence of
target disorders and healthcare needs. Furthermore, the growth of the market in
the rest of the world is attributed to the rising penetration of advanced
healthcare technologies in research organizations focused on viral vector and
plasmid DNA manufacturing incountries such as Saudi Arabia and the UAE.
Developing countries such as Argentina, Brazil, and Colombia, among others in
Latin America, are also key contributors to the growth of the market.
Segmentation
The global viral vector and plasmid DNA
manufacturing market share has been segmented
into vector type, workflow, disease type, application, and end user.
By vector type, the market is segmented into plasmid DNA,
viral vector, non-viral vector. The viral vector segment represented the dominant
share in 2020, owing to the rising prevalence of target diseases and disorders,
the effectiveness of viral vectors in gene therapy delivery, and rising
research activities focused on viral vector-based gene & cell therapies.
Based on the workflow, the market is segmented into upstream
processing, downstream processing. Downstream processing dominated the market
for viral vectors and plasmid DNA manufacturing in 2020. Increasing adoption of
downstream processing methods to help reduce contaminants originating from host
cells or culture media is driving the market growth of this segment.
On the basis of disease type, the market has been segmented into
genetic disorders, cancer, infectious diseases, and others. Cancer held the
largest market share in 2020 due to the increasing prevalence of cancer cases
globally. Furthermore, geneticdisordersare expected to be the fastest-growing
segment.
Based on application, the market is segmented into antisense &
RNAi therapy, gene therapy, cell therapy, vaccinology, and research. The
vaccinology segment dominated the market in 2020, owing tothe rising adoption
of viral vectors in vaccine development.
By end user, pharmaceutical & biopharmaceutical
companies and research institutes. Research institutes held a major share in
the global viral vectors and plasmid DNA manufacturing market. The increasing
number of research centers in gene and cell therapy coupled with rising
research activities for viral vectors and plasmid DNA is projected to increase
the demand for viral vectors in the global market.
Key Players
Some of the key players in the global Viral Vector and Plasmid DNA
Manufacturing market are Cognate BioServices, Inc. (US), Catalent Pharma
Solutions (US), Fujifilm Holdings Corporation (Japan), Johnson & Johnson
(US), Sanofi Corporation (France), F. Hoffmann-LA Roche Ltd (Switzerland), 4D
Molecular Therapeutics (US), Sirion Biotech GmbH (Germany), Voyager
Therapeutics (US), Thermo Fisher Scientific, Inc. (US), Gene Therapy Catapult
(UK), UniQure (Netherlands), MassBiologics (US), Renova Therapeutics (US) and
Shenzhen SiBionoGeneTech Co., Ltd (China).
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment